Feb 11 (Reuters) - Biophytis SA:
* PROTOCOL AMENDMENT OF SARA-INTEREST, A PHASE 2B CLINICAL TRIAL OF SARCONEOS (BIO101) IN SARCOPENIA, CLEARED BY FDA AND AFMPS
* FOLLOWING THIS CLEARANCE, SARA-INTEREST TRIAL TO RECRUIT 231 PATIENTS VERSUS. 334 INITIALLY PLANNED
* INTERIM ANALYSIS BY THE STUDY’S DATA SAFETY AND MONITORING BOARD (DSMB) EXPECTED IN Q2 2020
* REDUCTION IN PATIENT NUMBERS WILL NOT CHANGE OBJECTIVES, ENDPOINTS OR STATISTICAL POWER OF SARA-INTEREST CLINICAL TRIAL Source text : bit.ly/31KIk12 Further company coverage: (Gdansk Newsroom)
Our Standards: The Thomson Reuters Trust Principles.